Medication nonadherence during the first 24 weeks of treatment for
chronic hepatitis C was often deliberate and attributed to feeling well,
as opposed to forgetfulness or other factors, in a recent study.
Researchers evaluated adherence to treatment in a cohort of 401 patients with chronic HCV
genotype 1. All participants had been enrolled in the Virahep-C study
and received therapy with pegylated interferon (PEG) and ribavirin (RBV)
for 24 weeks, with responders receiving an additional 24 weeks (n=242).
Adherence was measured using the Medication Event Monitoring System,
which recorded when the medication container was opened via a computer
chip in the cap.